43
Participants
Start Date
June 12, 2023
Primary Completion Date
January 13, 2025
Study Completion Date
July 31, 2025
Spesolimab - solution for infusion
Solution for infusion
Placebo matching to spesolimab - solution for infusion
Solution for infusion
Spesolimab - solution for injection
Solution for injection
Placebo matching to spesolimab - solution for injection
Solution for injection
ASMC-IPSMC-skin and Veneral Diseases, Sofia
Westmead Hospital, Westmead
University Children Hospital Zürich, Zurich
AO Città della Salute e Scienza, Torino
Virginia Clinical Research, Inc., Norfolk
Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel
Medical University of South Carolina, Charleston
Hospital Tunku Azizah, Kuala Lumpur
Universitätsklinikum Heidelberg, Heidelberg
HOP Saint-Louis, Paris
Klinikum der Universität München AÖR, München
Mission Dermatology Center, Rancho Santa Margarita
Beijing Children's Hospital, Capital Medical University, Beijing
Shanghai Skin Disease Hospital, Shanghai
Xinhua Hospital Affiliated to Shanghai Jiaotong University, Shanghai
Dermatology Hospital, Chinese Academy of Medical Sciences, Nanjing
The Children's Hospital Zhejiang University School Of Medicine, Hangzhou
The First Affiliated Hospital, Zhejiang University, Hangzhou
Southern Medical University Dermatology Hospital, Guangzhou
Sourasky Medical Center, Tel Aviv
Yale University School of Medicine, New Haven
Istituto Dermopatico Dell'Immacolata - IDI - IRCCS, Roma
Nagoya University Hospital, Aichi, Nagoya
Juntendo University Urayasu Hospital, Chiba, Urayasu
Okayama University Hospital, Okayama, Okayama
Erasmus MC - Sophia Kinderziekenhuis, Rotterdam
ULS de São José, E.P.E. - Hospital Sto. António Capuchos, Lisbon
Queen Elizabeth University Hospital, Glasgow
Lead Sponsor
Boehringer Ingelheim
INDUSTRY